

Index

- A549 cell 139
adenosine triphosphate (ATP) 138
adhesion molecule 29, 55, 65
adjuvant arthritis 237
adjuvant therapy 228
airway epithelial cell 77
airway remodelling 176
alveolar macrophage 79, 112
alveolar monocyte-macrophage system 112
amiloride 136
aminoglycoside 72, 96, 248
amoxicillin 142
ampicillin 133
angiogenesis 233
ansamycin 96, 101, 249
anti-tumor effect, macrolides 82
AP-1 34, 55, 80, 207
apoptosis 37, 40, 55, 114, 172, 219
asthma 114, 133
asthmatic 114
azalide 50
azithromycin (AZM) 28, 31, 37, 52, 136, 152, 194, 211, 212, 219
- B-cell lymphoma leukemia-2 (Bcl-1)/Bax 114
Bcl-xL 115
benzylpyrimidine 250
bioactive phospholipids (PL) 50, 52, 176
biofilm 157, 174, 198
biphasic leukocyte response 31
Borrelia burgdorferi 236
bronchial epithelial cell 78
bronchiectasis 133
bronchoalveolar lavage (BAL) 65, 108
bronchoconstriction 176
bronchorrhea 133
- Ca²⁺ oscillation 139
Ca²⁺ release-activated Ca²⁺ (CRAC) channel 140
Ca²⁺-activated Cl channel 134, 136
cachexia 228
carbapenem antibiotics 72, 114, 250
caspase 115
C-C chemokine 111
CD8⁺ cell 108, 230
cefaclor 142
cefodizime 100, 250
cell-mediated immunity 107
cephalosporin 133
cephem 250
chemotactic factor 65
chemotaxis 65
Chlamydia pneumoniae 212, 213
chronic bronchiolitis 133
chronic granulomatous disease (CGD) 88, 91
chronic obstructive pulmonary disease (COPD) 72
chronic sinusitis 193
cilia 45
ciliary beat frequency (CBF) 46
ciprofloxacin 255

- Cl channel 135
Cl diffusion potential difference 137
Cl secretion 134, 142
clarithromycin (CAM) 28, 33, 52, 67, 108, 136, 137, 141, 142, 152, 194, 207–211, 213, 228
clindamycin 254
clofazimine 29, 96
corticosteroid 223
Crohn disease 238
erythromycin 209
CXC chemokines 239
cyclic AMP 51
cycline 96, 97, 101, 252
cystic fibrosis 70, 134, 167
cystic fibrosis transmembrane conductance regulator (CFTR) 134
cytokine production 133
cytokine 50, 69, 77, 80, 107, 133, 171, 206
cytotoxic CD8⁺ T cells 230
cytotoxic macrophage 230
cytotoxic T cell 108
- dapsone 36, 258
defensin 168
diffuse panbronchiolitis (DPB) 65, 97, 98, 133, 147, 227
diphenylamine-2-carboxylate 136
dirithromycin 50
doxycycline 212
dynamic viscosity, sputum 141, 174
- EGF-2 239
EGFR 125, 128
Elastase 55, 56
elastic modulus, sputum 141
electrolyte transport 133
electrophoretic mobility shift assay (EMSA) 81
endothelin-1 (ET-1) 175, 209
eosinophil 80
epidermal keratinocyte 72
epithelial integrity 51
epithelium 49
erythromycin (EM) 28, 29, 36, 37, 50, 52, 65, 108, 133, 135, 147, 206, 207, 209–212, 219, 227
extracellular signal regulated kinase (ERK)1/2 124
- Fas/Fas-ligand 114
FGF 240
FK506 138
FK-binding protein 138
fluoroquinolone 72, 82, 114
flurithromycin 56
fluticasone propionate 52
fosfomycin 36, 253
fusidic acid 36, 97, 253
- glycopeptide 72
GM-CSF 78, 223
goblet cell 124
grepafloxacin 256
group B streptococci (GBS) 236
gyrase B 254
- Haemophilus influenzae* 50, 150
hemolysin 57
HLA-DR 237
HMR 3004 52, 223
HMR 3647 52, 223
host defence and neutrophils 27
human leukocyte antigen (HLA)-B54 148
human peripheral T-lymphocyte 113
1-hydroxyphenazine 56
- IL-1 β 11, 69, 77
IL-2 107
IL-3 107
IL-4 86, 107, 228
IL-5 107
IL-6 82, 107, 227
IL-8 55, 65, 77, 124, 168, 233
IL-10 107

- IL-12 107, 227
immunostimulation and quinolones 31
inflammatory bowel disease (IBD) 238
inflammatory cytokine 77
inhibitor of NF- κ B (I κ B) 81
initial cellular defence reaction, enhancement by
 antibiotics 30
intercellular adhesion molecule (ICAM) 55, 69,
 172, 208, 221
interferon (IFN)- γ 107, 227
 β 2-integrin 55
interleukins 171
interstitial pneumonia 221
ion transport 156, 174
- josamycin 54, 136
Jurkat T lymphocyte 115
- keratinocyte 72
ketolide 50, 52, 223
- β -lactam 71, 96, 114, 250
leukocyte adhesion and clofazimine/
 roxithromycin 29
leukocytes and accumulation of antibiotics
 28
leukotriene B4 (LTB4) 68
levofloxacin 256
Lewis tumor 229
lincosamide 254
lipopolysaccharide (LPS) 123, 126
LPAF 52
LPC 52
lung cancer 228
lung injury 219
Lyme disease 236
lyso-PAF (LPAF) 50
lysophosphatidylcholine (LPC) 50
- Mac-1 69
macrolide antibiotics 6, 28–30, 32–34, 50, 65,
 82, 93, 97, 98, 101, 107, 136, 142
macrolide antibiotics, cellular accumulation
 28
macrolide inhibition of mucus secretion 33
macrolides and adhesion molecule expression
 29
macrolides and endothelial cell damage 29
macrolides and NF- κ B 34
macrolides and plasma exudation 30
macrolides in experimental inflammatory
 models 33
matrilysin 235
matrix metalloproteinase 35, 235
14-membered macrolide 136, 142
15-membered macrolide, azithromycin 136
16-membered macrolide 136
memory T cell 108
minocycline 252
minocycline, antirheumatic action 34
MIP-1 α 111
monobactam 250
motilin-like stimulating activity 83
moxifloxacin 31, 256
MUC2 198
MUC5AC 124, 126, 129
MUC5B 124, 129
mucin 169
mucociliary transport 133, 141
mucus 33, 49, 133, 173, 198
mucus hypersecretion 198
mucus secretion and clarithromycin 33
murine model of DPB 108
mycobacteria, non-tuberculous 177
Mycobacterium paratuberculosis 238
myeloma cells 237
myeloperoxidase (MPO) 89, 95
- NADPH oxidase 52, 87, 88
nasal polyp 198
neovascularization 233
neutrophil 27, 37, 52, 83, 91, 127, 156, 171,
 209, 219
neutrophil apoptosis 172

- neutrophil elastase 55, 56
neutrophil migration 55, 133, 172
neutrophil oxidant burst 172
neutrophil stimulation and macrolides/
 roxithromycin 30, 31
neutrophil-associated inflammatory disease
 72
nitric oxide (NO) 175
nitric oxide synthase 55
NK activity 228
non-small cell lung cancer 228
non-tuberculous mycobacteria 177
nuclear factor (NF)- κ B 34, 39, 55, 80, 81, 125,
 198, 207

otitis media with effusion 200
outwardly rectifying Cl channel (ORCC) 134
oxidative burst 87–89, 172

patch-clamp 136
penam 250
penem 250
penicillin 72, 133
phagocyte 54, 87, 88
phagocyte NADPH oxidase 88
phospholipase A2 237
platelet-activating factor (PAF) 50, 52
pneumolysin 49
polymorphonuclear neutrophil (PMN) 87, 209
polymyxin B 255
pro-apoptotic effects, antibiotics 37
proinflammatory cytokine production 206
prostaglandin E2 237
protease enzyme 50
 α -1-proteinase inhibitor (API) 56
Pseudomonas aeruginosa 5, 51, 57, 109, 124,
 150, 169, 173
Pseudomonas binding 169
Pseudomonas protease and hemolysin 57
pustulosis palmaris et plantaris 72
pyocyanin 56
pyometra 72

quinolones 31, 35, 93, 99, 114, 255
quinolones and apoptosis-inhibiting actions
 40
quorum sensing 5, 14, 159, 174

RANTES 111
reactive oxidants (ROS) 50, 54
regulation of the oxidative burst 89
reparan sulphate proteoglycan (HSPG) 235
resolution of inflammation, antibiotics 37
resolution of inflammation, NF- κ B 39
reverse transcription and polymerase chain
 reaction (RT-PCR) 78
rheumatoid arthritis (RA) 37, 236
rheumatoid arthritis and sulfonamides 37
rhinitis 141
rifampin 249
rifamycin 249
rolipram 52
roxithromycin 29, 31, 50, 52, 67, 108, 152,
 194, 206, 208–210, 212, 213, 234

salmeterol 52
SCID mouse 234
L-selectin 69
septic arthritis 236
short-circuit current 135, 136
sinusitis 72
spiramycin 54
sputum viscosity 141, 174
Streptococcus pneumoniae 49, 236
sub-MIC 5, 158
sulfone 258
sulfonamide 37, 258
syndecan-1 235

teicoplanin 255
tetracycline 34, 82, 133, 240, 252
TGF- α 126
Th1 cell 107, 230
Th1-derived cytokine 80
Th2 cell 107, 230

- Th2-derived cytokine 84, 107
- tilmicosin 37
- transepithelial potential difference 134, 136
- trimethoprim (TMP) 99, 250
- troleandomycin 211
- trovafloxacin 256
- tumor necrosis factor (TNF)- α 72, 77, 107, 223, 227
- uridine triphosphate (UTP) 139
- Ussing's technique 135
- vancomycin 255
- vascular cell adhesion molecule (VCAM) 55, 69, 172, 221
- vitamin E 54
- volume-sensitive Cl channel 134

The PIR-Series

Progress in Inflammation Research

Homepage: <http://www.birkhauser.ch>

Up-to-date information on the latest developments in the pathology, mechanisms and therapy of inflammatory disease are provided in this monograph series. Areas covered include vascular responses, skin inflammation, pain, neuroinflammation, arthritis cartilage and bone, airways inflammation and asthma, allergy, cytokines and inflammatory mediators, cell signalling, and recent advances in drug therapy. Each volume is edited by acknowledged experts providing succinct overviews on specific topics intended to inform and explain. The series is of interest to academic and industrial biomedical researchers, drug development personnel and rheumatologists, allergists, pathologists, dermatologists and other clinicians requiring regular scientific updates.

Available volumes:

- T Cells in Arthritis*, P. Miossec, W. van den Berg, G. Firestein (Editors), 1998
Chemokines and Skin, E. Kownatzki, J. Norgauer (Editors), 1998
Medicinal Fatty Acids, J. Kremer (Editor), 1998
Inducible Enzymes in the Inflammatory Response,
D.A. Willoughby, A. Tomlinson (Editors), 1999
Cytokines in Severe Sepsis and Septic Shock, H. Redl, G. Schlag (Editors), 1999
Fatty Acids and Inflammatory Skin Diseases, J.-M. Schröder (Editor), 1999
Immunomodulatory Agents from Plants, H. Wagner (Editor), 1999
Cytokines and Pain, L. Watkins, S. Maier (Editors), 1999
In Vivo Models of Inflammation, D. Morgan, L. Marshall (Editors), 1999
Pain and Neurogenic Inflammation, S.D. Brain, P. Moore (Editors), 1999
Anti-Inflammatory Drugs in Asthma, A.P. Sampson, M.K. Church (Editors), 1999
Novel Inhibitors of Leukotrienes, G. Folco, B. Samuelsson, R.C. Murphy (Editors), 1999
Vascular Adhesion Molecules and Inflammation, J.D. Pearson (Editor), 1999
Metalloproteinases as Targets for Anti-Inflammatory Drugs,
K.M.K. Bottomley, D. Bradshaw, J.S. Nixon (Editors), 1999
Free Radicals and Inflammation, P.G. Winyard, D.R. Blake, C.H. Evans (Editors), 1999
Gene Therapy in Inflammatory Diseases, C.H. Evans, P. Robbins (Editors), 2000
New Cytokines as Potential Drugs, S. K. Narula, R. Coffmann (Editors), 2000
High Throughput Screening for Novel Anti-inflammatories, M. Kahn (Editor), 2000
Immunology and Drug Therapy of Atopic Skin Diseases,
C.A.F. Bruijnzeel-Komen, E.F. Knol (Editors), 2000
Novel Cytokine Inhibitors, G.A. Higgs, B. Henderson (Editors), 2000
Inflammatory Processes. Molecular Mechanisms and Therapeutic Opportunities,
L.G. Letts, D.W. Morgan (Editors), 2000

- Cellular Mechanisms in Airways Inflammation*, C. Page, K. Banner, D. Spina (Editors), 2000
Inflammatory and Infectious Basis of Atherosclerosis, J.L. Mehta (Editor), 2001
Muscarinic Receptors in Airways Diseases, J. Zaagsma, H. Meurs, A.F. Roffel (Editors), 2001
TGF- β and Related Cytokines in Inflammation, S.N. Breit, S. Wahl (Editors), 2001
Nitric Oxide and Inflammation, D. Salvemini, T.R. Billiar, Y. Vodovotz (Editors), 2001
Neuroinflammatory Mechanisms in Alzheimer's Disease. Basic and Clinical Research,
J. Rogers (Editor), 2001
Disease-modifying Therapy in Vasculitides,
C.G.M. Kallenberg, J.W. Cohen Tervaert (Editors), 2001
Inflammation and Stroke, G.Z. Feuerstein (Editor), 2001
NMDA Antagonists as Potential Analgesic Drugs,
D.J.S. Sirinathsinghji, R.G. Hill (Editors), 2002
Migraine: A Neuroinflammatory Disease? E.L.H. Spierings, M. Sanchez del Rio (Editors), 2002
Mechanisms and Mediators of Neuropathic pain, A.B. Malmberg, S.R. Chaplan (Editors),
2002
Bone Morphogenetic Proteins. From Laboratory to Clinical Practice,
S. Vukicevic, K.T. Sampath (Editors), 2002
The Hereditary Basis of Allergic Diseases, J. Holloway, S. Holgate (Editors), 2002
Inflammation and Cardiac Diseases, G.Z. Feuerstein, P. Libby, D.L. Mann (Editors), 2003
Mind over Matter – Regulation of Peripheral Inflammation by the CNS,
M. Schäfer, C. Stein (Editors), 2003
Heat Shock Proteins and Inflammation, W. van Eden (Editor), 2003
Pharmacotherapy of Gastrointestinal Inflammation, A. Guglietta (Editor), 2004
Arachidonate Remodeling and Inflammation, A.N. Fonteh, R.L. Wykle (Editors), 2004
Recent Advances in Pathophysiology of COPD, P.J. Barnes, T.T. Hansel (Editors), 2004
Cytokines and Joint Injury, W.B. van den Berg, P. Miossec (Editors), 2004
Cancer and Inflammation, D.W. Morgan, U. Forssmann, M.T. Nakada (Editors), 2004
Bone Morphogenetic Proteins: Bone Regeneration and Beyond, S. Vukicevic, K.T. Sampath
(Editors), 2004